Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

A narrative review of genetic factors affecting fluoropyrimidine toxicity

Open access
Gmeiner, William H. · 2021 · Precision Cancer Medicine

Abstract

Objective: Our objective is to document progress in developing personalized therapy with fluoropyrimidine drugs (FPs) to improve outcomes for cancer patients and to identify areas requiring further investigation. Background: FPs including 5-fluorouracil (5-FU), are among the most widely used drugs for treating colorectal cancer (CRC) and other gastrointestinal (GI) malignancies. While FPs confer a survival benefit for CRC patients, serious systemic toxicities, including neutropenia, occur in ~30% of patients with lethality in 0.5−1% of patients. While serious systemic toxicities may occur in any patient, patients with polymorphisms in DPYD , which encodes the rate-limiting enzyme for pyrimidine degradation are at very high risk. Other genetic factors affecting risk for 5-FU toxicity, including miR-27a, are under investigation. Methods: Literature used to inform the text of this article was selected from PubMed.gov from the National Library of Medicine while regulatory documents were identified via Google search. Conclusions: Clinical studies to date have validated four DPYD polymorphisms ( DPYD *2A, DPYD *13, c.2846A>T, HapB3) associated with serious toxicities in patients treated with 5-FU. Genetic screening for these is being implemented in the Netherlands and the UK and has been shown to be a cost-effective way to improve outcomes. Factors other than DPYD polymorphisms (e.g., miR-27a, TYMS , ENOSF1, p53) also affect 5-FU toxicity. Functional testing for deficient pyrimidine catabolism {defined as [U] >16 ng/mL or [UH2]:[U] <10} is being implemented in France and has demonstrated utility in identifying patients with elevated risk for 5-FU toxicity. Therapeutic drug monitoring (TDM) from plasma levels of 5-FU during first cycle treatment also is being used to improve outcomes and pharmacokinetic-based dosing is being used to increase the percent of patients within optimal area under the curve (AUC) (18–28 mg*h/L) values. Patients maintained in the optimal AUC range experienced significantly reduced systemic toxicities. As understanding the genetic basis for increased risk of 5-FU toxicity becomes more refined, the development of functional-based methods to optimize treatment is likely to become more widespread.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/pcm-21-17

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Depiction of fluoropyrimidine metabolism and genetic factors influencing fluoropyrimidine toxicity. In most cancer patients >80% of 5-FU is degraded in the liver. However, for patients with certain DPYD polymorphisms reduced catabolism is accompanied by increased anabolic metabolism that perturbs RNA-mediated processes, particularly in the GI-tract and bone marrow, causing serious systemic toxicities. Several factors other than DPYD polymorphisms affect 5-FU toxicity including polymorphisms in miR-27a, polymorphisms in TYMS, an enzymatic target of 5-FU and levels of ENOSF1, a regulator of TYMS. p53 also regulates DPYD expression. The fluoropyrimidine polymer CF10 is directly converted to FdUMP and may circumvent issues related to genetic factors affecting 5-FU toxicity.
Figure 1 Depiction of fluoropyrimidine metabolism and genetic factors influencing fluoropyrimidine toxicity. In most cancer patients >80% of 5-FU is degraded in the liver. However, for patients with certain DPYD polymorphisms reduced catabolism is accompanied by increased anabolic metabolism that perturbs RNA-mediated processes, particularly in the GI-tract and bone marrow, causing serious systemic toxicities. Several factors other than DPYD polymorphisms affect 5-FU toxicity including polymorphisms in miR-27a, polymorphisms in TYMS, an enzymatic target of 5-FU and levels of ENOSF1, a regulator of TYMS. p53 also regulates DPYD expression. The fluoropyrimidine polymer CF10 is directly converted to FdUMP and may circumvent issues related to genetic factors affecting 5-FU toxicity.CC BY-NC-ND · PubMed Central
Figure 2 Depiction of strategies to reduce the occurrence of 5-FU-related toxicities. Pre-treatment screening is used to identify patients at elevated risk for 5-FU-related toxicities due to either polymorphisms in the DPYD gene associated with reduced DPD functional activity or measuring plasma Uracil values from which deficiencies in pyrimidine metabolism can be inferred. Initial 5-FU dosing may be reduced based on pre-treatment screening results. TDM permits 5-FU dose modulation based on plasma 5-FU levels during cycle 1 treatment such that subsequent cycles are more likely to be in the optimal range.
Figure 2 Depiction of strategies to reduce the occurrence of 5-FU-related toxicities. Pre-treatment screening is used to identify patients at elevated risk for 5-FU-related toxicities due to either polymorphisms in the DPYD gene associated with reduced DPD functional activity or measuring plasma Uracil values from which deficiencies in pyrimidine metabolism can be inferred. Initial 5-FU dosing may be reduced based on pre-treatment screening results. TDM permits 5-FU dose modulation based on plasma 5-FU levels during cycle 1 treatment such that subsequent cycles are more likely to be in the optimal range.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 27

Metadata

Authors
Gmeiner, W. H.
Affiliations
Wake Forest University Health Sciences (US)
Corresponding author
Gmeiner, William H.
Venue
Precision Cancer Medicine
Published
2021-12
Volume
4
Pages
38-38
ISSN
2617-2216 (ISSN-L)
OpenAlex
W3190206309
Cited by
25
References
81
Citations by year
2026: 3 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 4
FWCI
0.71
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
National Cancer Institute (R21CA218933, P30CA012197)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
fluoropyrimidine toxicity, 5-fluorouracil, DPYD polymorphisms, pharmacogenomics, personalized treatment, neutropenia, colorectal cancer, genetic screening, miR-27a, pyrimidine catabolism, therapeutic drug monitoring, pharmacokinetic dosing, area under the curve, thymidylate synthase, p53, gastrointestinal toxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A narrative review of genetic factors affecting fluoropyrimidine toxicity. https://app.cochat.ai/papers/10.21037/pcm-21-17
The paper
Gmeiner, W. H. (2021). A narrative review of genetic factors affecting fluoropyrimidine toxicity. Precision Cancer Medicine. https://doi.org/10.21037/pcm-21-17

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.